Form 4: Evommune CFO Reports Stock Transaction

Evommune, Inc. Chief Financial Officer Kyle Carver reported a transaction involving the purchase of 1,000 shares of common stock.

Summary

• Kyle Carver, Chief Financial Officer of Evommune, Inc., reported a transaction on July 8, 2026.
• Carver purchased 1,000 shares of common stock at a price of $13.26 per share.
• This transaction is noted as being matchable under Section 16(b) of the Securities Exchange Act of 1934 with prior sales.
• Specifically, the purchase is linked to the sale of 1,000 shares of common stock by Carver at $23.42 per share on May 28, 2026.
• Carver has agreed to pay the company $10,160, representing the profit realized from this short-swing transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a required disclosure of a short-swing trade with profit disgorgement, indicating compliance rather than a positive or negative operational development.

Positives

• The reporting person has agreed to pay the company the profit from the short-swing transaction, indicating compliance and a resolution of potential liability.

Negatives

• The transaction involves a short-swing trade, which is subject to profit disgorgement under Section 16(b) of the Securities Exchange Act of 1934.
• A profit of $10,160 was realized from the short-swing transaction, which must be paid back to the company.

Risks

• Potential for regulatory scrutiny related to short-swing trading, although the filing indicates a resolution.
• The need to disgorge profits from a short-swing trade may indicate suboptimal timing of transactions by management.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which details past transactions.

Management Comments

• The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026.
• The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, crucial for transparency in the biotechnology sector where executive trading activity can be closely watched.

Related Party Transactions

• The transaction involves a short-swing trade between an insider (CFO) and the company, requiring profit disgorgement.

Stakeholder Impact

• Shareholders benefit from the company recovering profits from a short-swing trade, reinforcing corporate governance and compliance.
• Management's adherence to Section 16(b) rules is maintained.

Next Steps

• Payment of $10,160 by the reporting person to Evommune, Inc. for the profit realized from the short-swing transaction.

Key Dates

Keywords

Form 4, SEC Filing, Evommune Inc., EVMN, Kyle Carver, Chief Financial Officer, Stock Transaction, Beneficial Ownership, Short-Swing Trading, Section 16(b)